Co-abuse of alprazolam augments the hepato-renal toxic effects of methylphenidate | Zendy

Shweta Sharma | Zendy; Meenu Dutt | Zendy; RavinderNaik Dharavath | Zendy; Tanzeer Kaur | Zendy; Navpreet Kaur | Zendy; Kanwaljit Chopra | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Co-abuse of alprazolam augments the hepato-renal toxic effects of methylphenidate

Author(s) -

Shweta Sharma,

Meenu Dutt,

RavinderNaik Dharavath,

Tanzeer Kaur,

Navpreet Kaur,

Kanwaljit Chopra

Publication year - 2020

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/ijp.ijp_758_19

Subject(s) - alprazolam , medicine , creatinine , methylphenidate , adverse effect , nephrotoxicity , renal function , physiology , kidney , pharmacology , endocrinology , anxiety , psychiatry , attention deficit hyperactivity disorder

Methylphenidate (MPH) is a first-line treatment option for attention-deficit hyperactive disorder and narcolepsy. MPH is one of the most abused psychostimulants by the adults and young population to stay awake, perform better, or improve concentration. The scanty reports say that the medical users or abusers mostly consider the administration of benzodiazepines to overcome the adverse effects, i.e., mood- and anxiety-related problems associated with MPH chronic abuse. This work aims to study the effect of alprazolam (ALZ) on MPH-associated adverse effects on liver and kidney.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research